PARADIGM-2: two parallel phase I studies of olaparib and radiotherapy or olaparib and radiotherapy plus temozolomide in patients with newly diagnosed glioblastoma, with treatment stratified by MGMT status.
Authors
Fulton, BShort, S
James, A
Nowicki, S
McBain, Catherine A
Jefferies, S
Kelly, C
Stobo, J
Morris, A
Williamson, A
Chalmers, A
Affiliation
Institute of Cancer Sciences, University of Glasgow, UKIssue Date
2018-01
Metadata
Show full item recordAbstract
Glioblastoma has a dismal prognosis and molecular targeted agents have failed to improve outcomes to date. PARADIGM-2 is a phase I dose escalation study evaluating olaparib plus radiotherapy ± temozolomide in newly diagnosed glioblastoma, using MGMT methylation status to stratify patients and inform treatment schedules.Citation
PARADIGM-2: two parallel phase I studies of olaparib and radiotherapy or olaparib and radiotherapy plus temozolomide in patients with newly diagnosed glioblastoma, with treatment stratified by MGMT status. 2018, 8: 12-16 Clin Transl Radiat OncolJournal
Clinical and translational radiation oncologyDOI
10.1016/j.ctro.2017.11.003PubMed ID
29594237Type
ArticleLanguage
enISSN
2405-6308ae974a485f413a2113503eed53cd6c53
10.1016/j.ctro.2017.11.003
Scopus Count
Collections
Related articles
- Nomograms for predicting survival of patients with newly diagnosed glioblastoma: prognostic factor analysis of EORTC and NCIC trial 26981-22981/CE.3.
- Authors: Gorlia T, van den Bent MJ, Hegi ME, Mirimanoff RO, Weller M, Cairncross JG, Eisenhauer E, Belanger K, Brandes AA, Allgeier A, Lacombe D, Stupp R
- Issue date: 2008 Jan
- The Combination PARP Inhibitor Olaparib With Temozolomide in an Experimental Glioblastoma Model.
- Authors: Hwang K, Lee JH, Kim SH, Go KO, Ji SY, Han JH, Kim CY
- Issue date: 2021 Jul-Aug
- Immunohistochemical analysis of O6-methylguanine-DNA methyltransferase (MGMT) protein expression as prognostic marker in glioblastoma patients treated with radiation therapy with concomitant and adjuvant Temozolomide.
- Authors: Younis SG, Khedr RA, El-Shorbagy SH
- Issue date: 2016 Mar
- N2M2 (NOA-20) phase I/II trial of molecularly matched targeted therapies plus radiotherapy in patients with newly diagnosed non-MGMT hypermethylated glioblastoma.
- Authors: Wick W, Dettmer S, Berberich A, Kessler T, Karapanagiotou-Schenkel I, Wick A, Winkler F, Pfaff E, Brors B, Debus J, Unterberg A, Bendszus M, Herold-Mende C, Eisenmenger A, von Deimling A, Jones DTW, Pfister SM, Sahm F, Platten M
- Issue date: 2019 Jan 1
- Pharmacological inhibition of poly(ADP-ribose) polymerase-1 modulates resistance of human glioblastoma stem cells to temozolomide.
- Authors: Tentori L, Ricci-Vitiani L, Muzi A, Ciccarone F, Pelacchi F, Calabrese R, Runci D, Pallini R, Caiafa P, Graziani G
- Issue date: 2014 Mar 5